JP2005535581A - 肺感染の拡大を制限する処方物 - Google Patents

肺感染の拡大を制限する処方物 Download PDF

Info

Publication number
JP2005535581A
JP2005535581A JP2004500839A JP2004500839A JP2005535581A JP 2005535581 A JP2005535581 A JP 2005535581A JP 2004500839 A JP2004500839 A JP 2004500839A JP 2004500839 A JP2004500839 A JP 2004500839A JP 2005535581 A JP2005535581 A JP 2005535581A
Authority
JP
Japan
Prior art keywords
formulation
surfactant
pulmonary
solution
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004500839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535581A5 (enExample
Inventor
デービッド エー． エドワーズ，
ハワード エー． ストーン，
Original Assignee
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ filed Critical プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Publication of JP2005535581A publication Critical patent/JP2005535581A/ja
Publication of JP2005535581A5 publication Critical patent/JP2005535581A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004500839A 2002-05-02 2003-05-01 肺感染の拡大を制限する処方物 Pending JP2005535581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37732702P 2002-05-02 2002-05-02
PCT/US2003/013707 WO2003092654A1 (en) 2002-05-02 2003-05-01 Formulations limiting spread of pulmonary infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011116395A Division JP2011157405A (ja) 2002-05-02 2011-05-24 肺感染の拡大を制限する処方物

Publications (2)

Publication Number Publication Date
JP2005535581A true JP2005535581A (ja) 2005-11-24
JP2005535581A5 JP2005535581A5 (enExample) 2006-06-22

Family

ID=29401482

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004500839A Pending JP2005535581A (ja) 2002-05-02 2003-05-01 肺感染の拡大を制限する処方物
JP2011116395A Pending JP2011157405A (ja) 2002-05-02 2011-05-24 肺感染の拡大を制限する処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011116395A Pending JP2011157405A (ja) 2002-05-02 2011-05-24 肺感染の拡大を制限する処方物

Country Status (6)

Country Link
US (1) US8858917B2 (enExample)
EP (1) EP1531795A4 (enExample)
JP (2) JP2005535581A (enExample)
AU (1) AU2003243191B2 (enExample)
CA (1) CA2483917C (enExample)
WO (1) WO2003092654A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545751A (ja) * 2010-11-12 2013-12-26 ゲッツ コンサルティング アンド プロジェクト マネジメント 修飾された免疫調節粒子

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483917C (en) 2002-05-02 2013-07-30 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
JP2008540680A (ja) 2005-05-18 2008-11-20 プルマトリックス インコーポレイテッド 粘膜内壁の生物物理学的な性質を変化させる製剤
US20100172845A1 (en) * 2007-05-29 2010-07-08 Board Of Regents Of The University Of Texas System Compositions and methods for treating mycobacterial infections
WO2010111640A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
US9504796B2 (en) * 2011-10-14 2016-11-29 The Trustees Of The Stevens Institute Of Technology Reducing ventilator-induced lung injury
US9693990B2 (en) 2011-10-14 2017-07-04 The Trustees Of The Stevens Institute Of Technology Use of rhodamine dyes to reduce alveolar surface tension
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
JP5478693B2 (ja) * 2012-03-23 2014-04-23 太平洋セメント株式会社 二次電池用正極活物質及びその製造方法
KR20220166879A (ko) 2012-06-21 2022-12-19 노쓰웨스턴유니버시티 펩티드 접합된 입자
IL303425A (en) 2013-03-13 2023-08-01 Cour Pharmaceuticals Dev Company Secondary vaccine particles for the treatment of inflammation
MX372849B (es) 2013-08-13 2020-07-06 Univ Northwestern Partículas conjugadas con péptidos.
US10391151B2 (en) 2015-06-29 2019-08-27 The Trustees Of The Stevens Institute Of Technology Dilute surfactant or isolated surfactant protein solution for the reduction of surface tension in the lung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH069428A (ja) * 1992-06-24 1994-01-18 Tokyo Tanabe Co Ltd 気道部ウィルス疾患の予防及び治療剤
JP2004513071A (ja) * 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37053A (en) 1862-12-02 Improved me at-cutter
DE3229179C2 (de) * 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4899914A (en) 1988-11-04 1990-02-13 Ciba-Geigy Corporation Method for producing a sterile preservative-free aerosol saline solution
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
CA2145948A1 (en) * 1994-04-06 1995-10-07 Wendell A. Ehrhart Floor covering having a (meth)acrylated, highly ethoxylated, aromatic polyester wear layer
US5863563A (en) 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
CA2213700C (en) * 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
WO1997029738A1 (en) * 1996-02-16 1997-08-21 The Administrators Of The Tulane Educational Fund Methods and compositions for treating eustachian tube dysfunction by inhalation
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
US5883084A (en) 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6669959B1 (en) 2000-07-18 2003-12-30 Aeropharm Technology Incorporated Modulated release particles for lung delivery
WO2002009574A2 (en) 2000-08-01 2002-02-07 Shofner Engineering Associates, Inc. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatment of the respiratory tract
AU2002245181B2 (en) 2000-12-21 2006-06-29 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
CA2483917C (en) 2002-05-02 2013-07-30 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070275091A1 (en) * 2004-03-30 2007-11-29 Malcolm King Compositions And Methods For Improved Mucus Function
US8627821B2 (en) * 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
US9708895B2 (en) 2013-05-07 2017-07-18 Halliburton Energy Services, Inc. Intrawell fluid injection system and method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH069428A (ja) * 1992-06-24 1994-01-18 Tokyo Tanabe Co Ltd 気道部ウィルス疾患の予防及び治療剤
JP2004513071A (ja) * 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545751A (ja) * 2010-11-12 2013-12-26 ゲッツ コンサルティング アンド プロジェクト マネジメント 修飾された免疫調節粒子

Also Published As

Publication number Publication date
US20090208581A1 (en) 2009-08-20
CA2483917A1 (en) 2003-11-13
EP1531795A4 (en) 2011-02-23
US8858917B2 (en) 2014-10-14
EP1531795A1 (en) 2005-05-25
CA2483917C (en) 2013-07-30
AU2003243191B2 (en) 2007-09-20
AU2003243191A1 (en) 2003-11-17
WO2003092654A1 (en) 2003-11-13
JP2011157405A (ja) 2011-08-18

Similar Documents

Publication Publication Date Title
US8858917B2 (en) Methods for limiting spread of pulmonary infections
AU2009225363B2 (en) Formulations for decreasing infectivity of pulmonary disease
Weber et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art
JP6840869B2 (ja) 肺障害の治療方法
US20070053844A1 (en) Formulations for alteration of biophysical properties of mucosal lining
JP2024069355A (ja) 閉塞性細気管支炎症候群（ｂｏｓ）の治療に使用するためのシクロスポリン製剤
Kanojia et al. Recent advancements and applications of inhalable microparticles based drug delivery systems in respiratory disorders
Shah et al. Current trends in inhaled pharmaceuticals: challenges and opportunities in respiratory infections treatment
US20050220720A1 (en) Formulations limiting spread of pulmonary infections
Scherließ et al. Novel formulation concept for particulate uptake of vaccines via the nasal associated lymphoid tissue
RU2479304C1 (ru) Стабильный раствор фенотерола гидробромида
AU2012202618A1 (en) Formulations for decreasing infectivity of pulmonary disease
HK1121064A (en) Formulations for alteration of biophysical properties of mucosal lining
Abdalaziz et al. Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment
Bhutkar et al. Novel Drug Delivery Systems in the Management of Asthma and Pulmonary Diseases
Albasarah Colloidal Carriers for Nebulized Drug Delivery
HK1165990A (en) Formulations for alteration of biophysical properties of mucosal lining

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091014

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111020